Skin lesion treatment device developer Clarify Medical said today it raised $3.6 million through a private financing round with existing an new investors.
Funds from the round will support the development of its handheld ultra violet B treatment system used to clear skin lesions for patients with chronic skin conditions such as psoriasis, eczema and vitiligo.
“We are delighted with the support we’ve received from our existing and new investors. Their vision, financial commitment and contributions of expertise have made this significant innovation in patient care possible,” board chair David Hale said in a press release.
The company’s Clarify UVB system is designed for home phototherapy use and can be linked to managing physicians through the user’s smartphones. Treatment with the device is guided through the users linked smartphone, and progress can be reviewed by physicians.
“Clarify’s system brings the proven treatment UVB therapy, currently challenging for many patients to access, into the comfort of home. Instead of making multiple weekly trips through traffic to a physician’s office or a UVB clinic to receive therapy for a few minutes, patients can deliver treatments themselves at times and locations that fit into their schedules. For busy dermatologists with office space and time constraints that often preclude offering UVB therapy, Clarify offers a way of offering a home treatment while continuing to monitor patient care,” CEO James Sweeney said in prepared remarks.
Clarify Medical said it plans to submit for FDA clearance in early 2017, with a slated launch later in the year.